Regeneron Pharmaceuticals (REGN) News
NASDAQ: REGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
746.54+6.97 (+0.94%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
REGN news summary
We found 31 recent headlines mentioning Regeneron Pharmaceuticals (REGN): 5 in the past week and 25 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, REGN is up 0.94% at $746.54. The most recent story, "Why Regeneron (REGN) is a Top Value Stock for the Long-Term", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Regeneron Pharmaceuticals headlines
- Why Regeneron (REGN) is a Top Value Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.Nasdaq
- Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKDBAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.NasdaqREGN, JNJ
- Repligen Corp Completes Acquisition Of BioLife Solutions(RTTNews) - Repligen Corp. (RGEN), a life sciences company, announced that it has completed the previously announced acquisition of BioLife Solutions, Inc. (BLFS), a developer and supplier of cell…NasdaqREGN, RGEN
- Regeneron sees nearly $0.18 per share earnings headwind in Q3Seeking Alpha
- Regeneron: The Easy Money Has Been Made (Rating Downgrade)Seeking Alpha
- iShares Biotechnology ETF Experiences Big InflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Biotechnology ETF (Symbol: IBB) where we have detected an…NasdaqIBB, REGN, NTRA, ARGX
- Sanofi, Regeneron Expand Immunology Alliance With New AntibodiesSNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.NasdaqREGN, SNY, AZN
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies TranscriptSeeking Alpha
- Regeneron's Ubamatamab, Trevogrumab Show Strong Results In Cancer And Obesity Studies(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN), a biopharmaceutical company, reported new clinical data for ubamatamab in advanced low-grade serous ovarian cancer (LGSOC) and trevogrumab in…Nasdaq
- Argus Research Upgrades Regeneron Pharmaceuticals to Buy from HoldFintel reports that on October 1, 2026, Argus Research upgraded their outlook for Regeneron Pharmaceuticals (NASDAQGS:REGN) (BIT:1REGN) from Hold to Buy.Regeneron Pharmaceuticals, Inc. is an American…Nasdaq
- Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 BillionAmylyx Stock: Why the Full Pipeline Story MattersRegeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize…Nasdaq
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - SlideshowSeeking Alpha
- Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinLLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.NasdaqREGN, PFE, NVO, LLY
- Sanofi, Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Bln(RTTNews) - Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) on Thursday announced an expanded global collaboration to develop and commercialise four next-generation, long-acting immunology…NasdaqREGN, SNY
- Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies(RTTNews) - On Thursday, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced the expansion of their global collaboration to develop and commercialize four next-generation, long-acting…NasdaqREGN, SNY
- REGN or ILMN: Which Is the Better Value Stock Right Now?REGN vs. ILMN: Which Stock Is the Better Value Option?NasdaqREGN, ILMN
- KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing NearsKodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.NasdaqKOD, REGN, ACIU, PGEN
- Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDVMIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.NasdaqMIRM, REGN, PGEN
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMDKeros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.NasdaqKROS, REGN, TAK, PGEN
- GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.NasdaqSNY, GSK, REGN
- Sanofi's New Drugs Poised to Drive Growth Beyond DupixentSNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.NasdaqSNY, REGN, AZN, LLY
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum TranscriptSeeking Alpha
- Is Regeneron Stock a Bargain Below $800?Key PointsRegeneron's latest financial results were strong.NasdaqREGN, SNY
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaREGN, MS
- New FDA Drug Approvals - August 2026(RTTNews) - The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.NasdaqBMY, BNTX, GILD, JAZZ
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha
- Regeneron: Why I Still See Upside After The RallySeeking Alpha
- Regeneron Pharmaceuticals, Inc. (REGN) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Regeneron Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- Regeneron: I'm Not Concerned About The Declining ROIC And Operating MarginsSeeking Alpha
- Regeneron Q2 Earnings Preview: Not Expecting Miracles - At Least In The Short TermSeeking Alpha